Progressive renal insufficiency associated with amiodarone-induced phospholipidosis

Kidney International

Volumn 74, Issue 10, 2008, Pages 1354-1357

  Pintavorn, Pairach ^a   Cook, William J ^b  

^a East Georgia Kidney and Hypertension Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE;

AGED; ANAMNESIS; ARTERIOSCLEROSIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FABRY DISEASE; FEMALE; FIBROSING ALVEOLITIS; HEART ARRHYTHMIA; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY TEST; LIPIDOSIS; MUTATIONAL ANALYSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; PHOSPHOLIPIDS; RENAL INSUFFICIENCY; UP-REGULATION;

EID: 55249111287     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.229     Document Type: Article

References (16)

1. Albay D, Adler SG, Philipose J et al. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 2005; 18: 733-738.
2. Müller-Höcker J, Schmid H, Weiss M et al. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum Pathol 2003; 34: 285-289.
3. Bracamonte ER, Kowalewska J, Starr J et al. Latrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006; 48: 844-850.
4. Woywodt A, Hellweg S, Schwarz A et al. A wild zebra chase. Nephrol Dial Transplant 2007; 22: 3074-3077.
5. Jessurun GAJ, Crijns HJGM. Amiodarone pulmonary toxicity. Br Med J 1997; 314: 619-620.
6. Hauser AC, Lorenz M, Sunder-Plassmann G. The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. J Intern Med 2004; 255: 629-636.
7. Agoston M, Orsi F, Feher E et al. Silymarin and vitamin E reduce amiodarone-induced lysosomal phosphoplipidosis in rats. Toxicology 2003; 190: 231-241.
8. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med 2001; 226: 825-830.
9. Liu FL, Cohen RD, Downar E et al. Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. Thorax 1986; 41: 100-105.
10. Martin WJ, Kachel DL, Vilen T et al. Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J Pharmacol Exp Ther 1989; 251: 272-278.
11. Fredman P, Klinghardt GW, Svennerholm L. Effect of chloroquine on the activity of some lysosomal enzymes involved in ganglioside degradation. Biochem Biophys Acta 1987; 917: 1-8.
12. Shaikh NA, Downar E, Butany J. Amiodarone, an inhibitor of phospholipase activity: a comprehensive study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem 1987; 76: 163-172.
13. Inagaki M, Katsumoto T, Nanba E et al. Lysosomal glycosphingolipid storage in chloroquine-induced alpha-galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease. Acta Neuropathol 1993; 85: 272-279.
14. D'Amico DJ, Kenyon KR. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981; 4: 67-76.
15. Chew E, Ghosh M, McCulloch C. Amiodarone-induced cornea verticillata. Can J Ophthalmol 1982; 17: 96-99.
16. Warnock DG. Fabry disease: diagnosis and management, with emphasis on renal manifestations. Curr Opin Nephrol Hypertens 2005; 14: 87-95.